Marrone Bio Innovations, Inc. (NASDAQ:MBII) has a beta value of 0.27 and has seen 1,475,176 shares traded in the last trading session. The company, currently valued at $155.1 Million, closed the last trade at $1.04 per share which meant it lost $0 on the day or -0.95% during that session. The MBII stock price is -66.35% off its 52-week high price of $1.73 and 41.35% above the 52-week low of $0.61. If we look at the company’s 10-day average daily trading volume, we find that it stood at 425.07 Million shares traded. The 3-month trading volume is 293.07 Million shares.
The consensus among analysts is that Marrone Bio Innovations, Inc. (MBII) is a Buy stock at the moment, with a recommendation rating of 2. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 3 have rated it as a Hold, with 3 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.04.
Marrone Bio Innovations, Inc. (NASDAQ:MBII) trade information
Despite being -0.95% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Friday, Jun 26 when the MBII stock price touched $1.19 or saw a rise of 12.61%. Year-to-date, Marrone Bio Innovations, Inc. shares have moved 2.97%, while the 5-day performance has seen it change -0.95%. Over the past 30 days, the shares of Marrone Bio Innovations, Inc. (NASDAQ:MBII) have changed 0.97%. Short interest in the company has seen 2.16 Million shares shorted with days to cover at 0.01.
Wall Street analysts have a consensus price target for the stock at $1.91, which means that the shares’ value could jump 83.65% from current levels. The projected low price target is $1.4 while the price target rests at a high of $2.5. In that case, then, we find that the current price level is +140.38% off the targeted high while a plunge would see the stock lose 34.62% from current levels.
Marrone Bio Innovations, Inc. (MBII) estimates and forecasts
Figures show that Marrone Bio Innovations, Inc. shares have underperformed across the wider relevant industry. The company’s shares have lost 0% over the past 6 months, with this year growth rate of -50%, compared to -22.9% for the industry. Other than that, the company has, however, increased its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are 33.3% and 71.4% for the next quarter. Revenue growth from the last financial year stood is estimated to be +37.4%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +32.9% over the past 5 years. Earnings growth for 2020 is a modest -57.8% while over the next 5 years, the company’s earnings are expected to increase by 0%.
Marrone Bio Innovations, Inc. (NASDAQ:MBII)’s Major holders
Insiders own 0.8% of the company shares, while shares held by institutions stand at 73.29% with a share float percentage of 73.88%. Investors are also buoyed by the number of investors in a company, with Marrone Bio Innovations, Inc. having a total of 76 institutions that hold shares in the company. The top two institutional holders are Waddell & Reed Financial Inc. with over 24.4 Million shares worth more than $19.93 Million. As of March 30, 2020, Waddell & Reed Financial Inc. held 16.77% of shares outstanding.
The other major institutional holder is Ardsley Advisory Partners, with the holding of over 13.53 Million shares as of March 30, 2020. The firm’s total holdings are worth over $11.05 Million and represent 9.3% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Ivy Science & Technology Fund and Vanguard Total Stock Market Index Fund. As of March 30, 2020, the former fund manager holds about 16% shares in the company for having 23285292 shares of worth $19.02 Million while later fund manager owns 2.12 Million shares of worth $1.73 Million as of March 30, 2020, which makes it owner of about 1.46% of company’s outstanding stock.